The Short-term Clinical Efficacy And Safety Of Paclitaxel Com Bind With Cisplatin By Hyperthermic Intraperitoneal Perfusin In The Treatment Of Gastric Cancer With Ascites

Objective:This thesis is to investigate the efficiency and safety of paclitaxel combind with cisplatin by hyperthermic intraperitoneal perfusin in the treatment of gastric cancer with ascites.Methods:A total of 75 patients of gastric cancer with ascites from May2014 to December 2016 were collected.According to the different treatment methods,the patients were divided into the observation group(n=40)and the control group(n=35).The two groups were treated with intravenous infusion of paclitaxel 175 mg/m2 for first days.Cisplatin D1 60mg,D5 60mg:the observation group was injected into the abdominal cavity by the thermostatic perfusion apparatus with constant temperature(43℃),and the control group was injected into the abdominal cavity with normal saline 500 ml,3 week for 1 cycles.After 4-6cycles.The data of clinical treatment effect,serum carcinoembryonic antigen concentration,the quality of life and the complications of the two groups were statistically analyzed.1-year cumulative survival rates were compared between the two groups.Results:The effective rate of observation group was significantly higher than the control group(60.00%vs 37.14%,X~2=3.902,P=0.048).Though the serum CEA decrease after treatment by the two different therapeutic regimens(P<0.05),the decreases in the observation group were more significant than the control group(P<0.05).There were no significant difference in the 1-year cumulative survival rate and the Incidence of adverse reactions between the two groups after treatment.Conclusion:Intravenous infusion of paclitaxel combind with cisplatin by hyperthermic intraperitoneal perfusin in the treatment of gastric cancer with ascites has a better short-term clinical effect,because It can improve some patients’quality of life and may prolong the survival time of some patients,and the adverse drug reaction can be tolerated.